Dr. Reddy's Laboratories launches Chlorthalidone Tablets, USP in the U.S. Market
Deepthi | Myequity news | Date : 28-11-2018 11:20:00 IST
Dr. Reddy's Laboratories Ltd. launched Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton (chlorthalidone) Tablets, approved by the U.S. Food and Drug Administration (USFDA).
The Hygroton brand and generic had U.S. sales of approximately $122 million MAT for the most recent twelve months ending in September 2018 according to IMS Health*.
Dr. Reddy's Chlorthalidone Tablets, USP are available in 25 mg tablets in the bottle-count sizes of 100 and 1000, and 50 mg tablets in the bottle-count size of 100.
About Dr. Reddy's:
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.